1. Home
  2. RPTX vs OPI Comparison

RPTX vs OPI Comparison

Compare RPTX & OPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPTX
  • OPI
  • Stock Information
  • Founded
  • RPTX 2016
  • OPI 2009
  • Country
  • RPTX Canada
  • OPI United States
  • Employees
  • RPTX N/A
  • OPI N/A
  • Industry
  • RPTX Biotechnology: Pharmaceutical Preparations
  • OPI Real Estate Investment Trusts
  • Sector
  • RPTX Health Care
  • OPI Real Estate
  • Exchange
  • RPTX Nasdaq
  • OPI Nasdaq
  • Market Cap
  • RPTX 38.3M
  • OPI N/A
  • IPO Year
  • RPTX 2020
  • OPI 2009
  • Fundamental
  • Price
  • RPTX $1.36
  • OPI $0.27
  • Analyst Decision
  • RPTX Strong Buy
  • OPI Strong Buy
  • Analyst Count
  • RPTX 3
  • OPI 1
  • Target Price
  • RPTX $4.50
  • OPI $7.00
  • AVG Volume (30 Days)
  • RPTX 508.5K
  • OPI 635.6K
  • Earning Date
  • RPTX 05-20-2025
  • OPI 04-30-2025
  • Dividend Yield
  • RPTX N/A
  • OPI 14.72%
  • EPS Growth
  • RPTX N/A
  • OPI N/A
  • EPS
  • RPTX N/A
  • OPI N/A
  • Revenue
  • RPTX $53,477,000.00
  • OPI $476,159,000.00
  • Revenue This Year
  • RPTX N/A
  • OPI N/A
  • Revenue Next Year
  • RPTX $7.14
  • OPI N/A
  • P/E Ratio
  • RPTX N/A
  • OPI N/A
  • Revenue Growth
  • RPTX 4.58
  • OPI N/A
  • 52 Week Low
  • RPTX $0.89
  • OPI $0.28
  • 52 Week High
  • RPTX $4.29
  • OPI $3.02
  • Technical
  • Relative Strength Index (RSI)
  • RPTX 59.23
  • OPI 29.91
  • Support Level
  • RPTX $1.25
  • OPI $0.30
  • Resistance Level
  • RPTX $1.48
  • OPI $0.42
  • Average True Range (ATR)
  • RPTX 0.11
  • OPI 0.04
  • MACD
  • RPTX 0.01
  • OPI 0.00
  • Stochastic Oscillator
  • RPTX 57.14
  • OPI 5.19

About RPTX Repare Therapeutics Inc.

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Share on Social Networks: